FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2715266844> ?p ?o ?g. }

• W2715266844 abstract "2032 Background: Routine clinical use of bevacizumab (Bev) in recurrent glioblastoma (rGBM) is controversial, as no large RCT has shown a survival advantage. We describe treatment algorithms, survival (OS), quality-adjusted survival (QAS) as well as costs of patients (pts) with GBM treated at an academic hospital in Switzerland, where Bev is registered and reimbursed for rGBM. Methods: Pts’ and treatment characteristics from diagnosis until death (including neurological symptoms and toxicities) of all pts over a 5-year period were retrospectively retrieved from our GBM database. For each treatment period (1 st -line, recurrence and “best supportive care”) time to next treatment (TNT), OS and QAS were calculated and modelled for prognostic factors (Cox regression). QAS was evaluated as previously described (Murray et al). In- and out-patient costs were calculated from time of diagnosis until death in respect of Bev treatment (+Bev vs. –Bev). Results: 82 newly diagnosed GBM pts with a median age of 66 years (range 39-85), median KPS of 90% (range 50-100%), who were treated with 1 (n = 75), 2 (n = 36) or 3 (n = 14) lines of therapy, respectively, lived for a median OS of 11.9 (SD 9.7) months (mos). QAS was 5.3 (SD 6.9) mos i.e. 44% of the numerical survival time. 40% of patients were treated with Bev at 1 st or 2 nd recurrence. Pts, who were selected for BEV treatment, had a longer time from diagnosis to 2 nd line treatment (median 5.2 (SD 6.3) mos) as compared to pts in the -Bev group (median 2.1 (SD 1.8) mos). Younger age and Bev treatment were associated with longer OS and QAS. QAS to OS ratio was 52% (9.4 out of 18.1 mos) for BEV treated patients and 34% (2.8 out of 8.2 mos) for the –Bev group, respectively. Bev treatment increased the overall treatment costs by 1.7x. The population adjusted incremental cost-effectiveness ratio (ICER) was CHF 75,669 per life year gained. Conclusions: QAS in patients with GBM is short (one third to half of OS). In our cohort, pts selected for Bev treatment had longer OS and longer QAS - at costs below the accepted threshold of 100,000 CHF per life year gained. Whether this gain of lifetime is a direct result of Bev treatment or a consequence of a selection bias needs to be addressed prospectively." @default.
• W2715266844 created "2017-06-30" @default.
• W2715266844 creator A5010048035 @default.
• W2715266844 creator A5026619998 @default.
• W2715266844 creator A5070477073 @default.
• W2715266844 creator A5086220270 @default.
• W2715266844 creator A5090715927 @default.
• W2715266844 date "2017-05-20" @default.
• W2715266844 modified "2023-09-26" @default.
• W2715266844 title "Benefits and costs of bevacizumab in recurrent glioblastoma: A quality adjusted survival and cost analysis (EVALUATE)." @default.
• W2715266844 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.2032" @default.
• W2715266844 hasPublicationYear "2017" @default.
• W2715266844 type Work @default.
• W2715266844 sameAs 2715266844 @default.
• W2715266844 citedByCount "1" @default.
• W2715266844 countsByYear W27152668442021 @default.
• W2715266844 crossrefType "journal-article" @default.
• W2715266844 hasAuthorship W2715266844A5010048035 @default.
• W2715266844 hasAuthorship W2715266844A5026619998 @default.
• W2715266844 hasAuthorship W2715266844A5070477073 @default.
• W2715266844 hasAuthorship W2715266844A5086220270 @default.
• W2715266844 hasAuthorship W2715266844A5090715927 @default.
• W2715266844 hasConcept C10515644 @default.
• W2715266844 hasConcept C126322002 @default.
• W2715266844 hasConcept C143998085 @default.
• W2715266844 hasConcept C187212893 @default.
• W2715266844 hasConcept C2776194525 @default.
• W2715266844 hasConcept C2776694085 @default.
• W2715266844 hasConcept C2777802072 @default.
• W2715266844 hasConcept C3019894029 @default.
• W2715266844 hasConcept C502942594 @default.
• W2715266844 hasConcept C50382708 @default.
• W2715266844 hasConcept C71924100 @default.
• W2715266844 hasConceptScore W2715266844C10515644 @default.
• W2715266844 hasConceptScore W2715266844C126322002 @default.
• W2715266844 hasConceptScore W2715266844C143998085 @default.
• W2715266844 hasConceptScore W2715266844C187212893 @default.
• W2715266844 hasConceptScore W2715266844C2776194525 @default.
• W2715266844 hasConceptScore W2715266844C2776694085 @default.
• W2715266844 hasConceptScore W2715266844C2777802072 @default.
• W2715266844 hasConceptScore W2715266844C3019894029 @default.
• W2715266844 hasConceptScore W2715266844C502942594 @default.
• W2715266844 hasConceptScore W2715266844C50382708 @default.
• W2715266844 hasConceptScore W2715266844C71924100 @default.
• W2715266844 hasLocation W27152668441 @default.
• W2715266844 hasOpenAccess W2715266844 @default.
• W2715266844 hasPrimaryLocation W27152668441 @default.
• W2715266844 hasRelatedWork W2035972952 @default.
• W2715266844 hasRelatedWork W2049433775 @default.
• W2715266844 hasRelatedWork W2129930802 @default.
• W2715266844 hasRelatedWork W2132798780 @default.
• W2715266844 hasRelatedWork W2175619860 @default.
• W2715266844 hasRelatedWork W2466655253 @default.
• W2715266844 hasRelatedWork W2558944992 @default.
• W2715266844 hasRelatedWork W2602217796 @default.
• W2715266844 hasRelatedWork W2608349617 @default.
• W2715266844 hasRelatedWork W2674472259 @default.
• W2715266844 hasRelatedWork W2735229934 @default.
• W2715266844 hasRelatedWork W2736995408 @default.
• W2715266844 hasRelatedWork W2884657914 @default.
• W2715266844 hasRelatedWork W2907794764 @default.
• W2715266844 hasRelatedWork W2947461731 @default.
• W2715266844 hasRelatedWork W2957727389 @default.
• W2715266844 hasRelatedWork W3014485921 @default.
• W2715266844 hasRelatedWork W3025003528 @default.
• W2715266844 hasRelatedWork W3046320670 @default.
• W2715266844 hasRelatedWork W3184041930 @default.
• W2715266844 isParatext "false" @default.
• W2715266844 isRetracted "false" @default.
• W2715266844 magId "2715266844" @default.
• W2715266844 workType "article" @default.